Welcome to our new website! If this is the first time you are logging in on the new site, you will need to reset your password. Please contact us at email@example.com if you need assistance.
The site navigation utilizes arrow, enter, escape, and space bar key commands. Left and right arrows move
across top level links and expand / close menus in sub levels. Up and Down arrows will open main level
menus and toggle through sub tier links. Enter and space open menus and escape closes them as well. Tab
will move on to the next part of the site rather than go through menu items.
The regulatory function is vital in making safe and effective healthcare products available worldwide. Individuals who ensure regulatory compliance and prepare submissions, as well as those whose main job function is clinical affairs or quality assurance are all considered regulatory professionals.
One of our most valuable contributions to the profession is the Regulatory Code of Ethics. The Code of Ethics provides regulatory professionals with core values that hold them to the highest standards of professional conduct.
Your membership opens the door to free learning resources on demand. Check out the Member Knowledge Center for free webcasts, publications and online courses.
Like all professions, regulatory is based on a shared set of competencies. The Regulatory Competency Framework describes the essential elements of what is required of regulatory professionals at four major career and professional levels.
Join the brightest minds in regulatory at the annual Regulatory Convergence. See the global regulatory community in action. Intensive workshops. Topical sessions. Meet ups with regulators. This is where it all comes together.
For 20 years, our flagship publication, Fundamentals of US Regulatory Affairs, has been giving regulatory professionals the insights and answers they need, right at their fingertips.
There are hundreds of RAC testing centers available worldwide. Any of the four RAC exams (US, EU, CAN or Global) may be taken at any location. Find an upcoming exam at a location near you.
Posted 20 April 2012 | By Alexander Gaffney, RAC
Swiss pharmaceuticals manufacturer Novartis AG received mixed news from European and American regulators on 18 April, with the European Medicines Agency (EMA) approving its multiple sclerosis drug GIlenya with some additional warnings, and the US Food and Drug Administration (FDA) demanding a phase III trial for its hepatitis C drug alisporivir be halted after safety concerns were raised.
EMA's decision on GIlenya came after some concerns about the drug's safety were raised, which had led some to believe the drug might not receive approval from the European regulatory body. The drug, used to treat adults with highly active multiple sclerosis, was associated with cardiovascular-related adverse events and at least one sudden and unexpected death occurring in a US patient.
EMA said in a statement "there is clear evidence of the benefit of Gilenya in relapsing-remitting multiple sclerosis," but that given the product's known cardiovascular risks, the product must come with warnings to discourage its use in patients with heart conditions.
News of the potential blockbuster's approval was tempered by FDA's demands that Novartis halt a phase III of its hepatitis C drug alisporivir after patients were reported to be suffering from pancreatitis and one trial participant died.
The company has not yet determined if the patient's death was related to taking alisporivir, reported The Dow Jones Newswire, but FDA has ordered the trial be put on hold until the case is properly investigated.
EMA's Decision on Gilenya
EMA - European Medicines Agency gives new advice to better manage risk of adverse effects on the heart with Gilenya
EMA - European Medicines Agency gives new advice to better manage risk of adverse effects on the heart with Gilenya (Q&A)
Reuters - New warnings on Novartis MS pill in Europe and U.S
PharmPro - Novartis makes changes to label of MS drug
Wall Street Journal - Setback for Novartis Hepatitis Drug
Bloomberg - Novartis halts hepatitis drug trial after death
BioCentury - FDA places hold on alisporivir Phase III trial
Tags: Stopped, Phase 3, Phase III, Alisporovir, Hepatitis C, HCV, Gilenya, Novartis AG, MS, Novartis, Latest News, clinical trial
Regulatory Focus newsletters
All the biggest regulatory news and happenings.
This article provides a variety of websites with important information on recent changes to FDA guidances and tables ...